Table 3.
Final model of the stepwise regression analysis for pre-therapy factors associated with pre-therapy total cholesterol levels in CHC patients
| Variants | Estimated β | 95% CI β | p Values |
|---|---|---|---|
| Intercept | 72.37141 | 51.32538 ~ 93.41744 | 6.7X10−11 |
| Age (yr) | 0.312191 | 0.048357 ~ 0.576025 | 0.020967 |
| HS-CRP (mg/dL) | 0.88786 | 0.184982 ~ 1.590738 | 0.013773 |
| HDL-C (mg/dL) | 1.240587 | 1.009331 ~ 1.471843 | 1.32 X10−22 |
| TGs (mg/dL) | 0.231622 | 0.169855 ~ 0.293389 | 1.46 X10−12 |
| LC (0:no; 1: yes) | −12.655 | −19.9286~-5.3814 | 0.000727 |
| rs61330082 genotype (CC:0; CT:1; TT:2)* | 5.195503 | 1.076845 ~ 9.314161 | 0.013902 |
CHC: chronic hepatitis C virus infection; CI: confidence; HS-CRP: high-sensitivity C-reactive protein; HDL-C: high-density lipoprotein cholesterol; TGs: triglycerides; LC: liver cirrhosis; *: additive model.